News End of the line for Sanofi's SERD amcenestrant as it fails f... Sanofi has called time on breast cancer candidate amcenestrant – at one time one of its top pipeline prospects – after it missed the mark in another clinical trial.
R&D Health Innovators – Jennifer Schranz In the rare and ultra-rare disease space, the paucity of both data and patients makes everything about research and development more complicated.
R&D Inside the new world of healthcare data These days, real-world data collection is in vogue and not hard to come by in healthcare research.